Johnson & Johnson (JNJ) Debuts New Coronary Catheter In The U.S.

Johnson & Johnson (NYSE:JNJ) introduced the Shockwave C2 Aero Fly Coronary IVL Catheter in the U.S. for calcified coronary lesions. The new catheter is described by the company as a next generation device intended to improve procedural efficiency in coronary interventions. Johnson & Johnson reported long term Phase 3 and extension trial data for TREMFYA and ICOTYDE in Crohn’s disease and plaque psoriasis. The fresh coronary IVL launch and TREMFYA and ICOTYDE data only capture part of the...